FocalTherics Launches First Commercial Endometriosis Program in Europe
Event summary
- FocalTherics launched its first commercial endometriosis Focal One® Program in Europe, treating initial patients at Toulouse University Hospital on June 30, 2026.
- The program targets deep infiltrating endometriosis, a condition affecting approximately 38 million women worldwide.
- Focal One Robotic HIFU uses high-intensity focused ultrasound technology to ablate lesions without surgery.
- More than 10 hospitals are in the company’s active clinical training pathway across Europe, the UK, and Latin America.
The big picture
FocalTherics’ launch of the Endometriosis Focal One Program marks a strategic shift in treating deep infiltrating endometriosis, offering a minimally invasive alternative to conventional surgery. The program aligns with broader industry trends toward precision medicine and organ-sparing treatments, potentially reshaping the treatment paradigm for millions of women. Success will depend on physician training, reimbursement structures, and market acceptance.
What we're watching
- Clinical Adoption
- How quickly FocalTherics can expand the Endometriosis Focal One program across additional hospitals in Europe, the UK, and Latin America.
- Market Penetration
- Whether the company can sustain momentum in a competitive landscape dominated by traditional surgical approaches.
- Regulatory Dynamics
- The pace at which FocalTherics secures additional regulatory approvals beyond CE Mark certification to broaden its market reach.
Related topics